Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 325-330

  Lamon Fava, Stefania ^a   Herrington, David M ^b   Reboussin, David M ^b   Sherman, Michelle ^a   Horvath, Katalin ^a   Schaefer, Ernst J ^a   Asztalos, Bela F ^a  

^a TUFTS UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiography; Coronary heart disease; Hormone therapy; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PLACEBO;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET RESTRICTION; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CHOLESTEROL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE PROGRESSION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONES; HUMANS; LIPOPROTEINS, HDL; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE;

EID: 67349147910     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.020     Document Type: Article

References (46)

1. Hulley S.B., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
2. Herrington D.M., Reboussin D.M., Brosnihan B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
3. Clarke S., Kelleher J., Lloyd-Jones H., et al. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT atherosclerosis study. Brit J Obstet Gynaec 109 (2002) 1056-1062
4. Angerer P., Stork S., Kothny W., et al. Effects of oral postmenopausal hormone replacement on progression of atherosclerosis. A randomized, controlled trial. Arterioscl Throm Vas 21 (2001) 262-268
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
6. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
7. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of epidemiologic evidence. Prev Med 20 (1991) 47-63
8. Clarkson T., Anthony M., and Wagner J. A comparison of tibolone and conjugated equine estrogens effects on coronary atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocr Metab 86 (2001) 5396-5404
9. Rossouw J., Prentice R., Manson J.A., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
10. Smith N., Keckbert S., Lemaitre R., et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thormbosis. JAMA 292 (2004) 1581-1587
11. Seli E., Guzeloglu-Kayisli O., Cakman H., et al. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression. J Clin Endocr Metab 91 (2006) 4995-5001
12. Ridker P.M., Hennekens C.H., Rifai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
13. Mendelsohn M., and Karas R. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2007) 1583-1587
14. McNamara J.R., Shah P.K., Nakajiam K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154 (2001) 229-236
15. Asztalos B.F., Collins D., Cupples L.A., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscl Throm Vas 25 (2005) 2185-2191
16. Asztalos B.F., Cupples L.A., Demissie S., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscl Throm Vas 24 (2004) 2181-2187
17. Herrington D.M., Reboussin D.M., Klein K., et al. Estrogen Replacement and Atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials 21 (2000) 257-285
18. McNamara J.R., and Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma lipoprotein fractions. Clin Chim Acta 166 (1987) 1-8
19. Burstein M., and Samaille J. Sur un dosage rapide du cholesterol lie aux alpha- et aux beta-lipoproteines du serum. Clin Chim Acta 5 (1960) 609
20. Contois J., McNamara J., Lammi-Keefe C., et al. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 42 (1996) 507-514
21. McNamara J.R., Shah P.K., Nakajima K., et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin Chem 44 (1998) 1224-1232
22. Asztalos B.F., Sloop C.H., Wong L., et al. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1169 (1993) 291-300
23. Wilt T.J., Bloomfield H.E., MacDonald R., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 (2004) 1427-1436
24. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998) 1453-1460
25. Athyros V., Mikhailidis D., Papageorgiou A., et al. Effect of atorvastatin on high density lipoprotein-cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 20 (2004) 627-637
26. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
27. Lamon-Fava S., Postfai B., Asztalos B.F., et al. Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high-density lipoproteins. Metabolism 52 (2004) 1330-1336
28. Sanada M., Nakagawa H., Kodama I., et al. The effect of hormone replacement therapy on metabolism of lipoprotein remants in postmenopausal women. Maturitas 34 (2000) 75-82
29. Westerveld H., Kock L.A.W., Rijn H.J.M., et al. 17 Beta-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocr Metab 80 (1995) 249-253
30. Ossewaarde M., Dallinga-Thie G., Bots M., et al. Treatment with hormonal replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest 33 (2003) 376-382
31. Bittner V., Tripputi M., Hsia J., et al. Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen trial. Am Heart J 148 (2004) 293-299
32. Walsh B.W., Schiff I., Rosner B., et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New Engl J Med 325 (1991) 1196-1204
33. Bruning J.C., Lingohr P., Gillette J., et al. Estrogen receptor alpha and Sp1 interact in the induction of the low density lipoprotein-receptor. J Steroid Biochem 86 (2003) 113-121
34. Lamon-Fava S., Postfai B., Diffenderfer M., et al. Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women. Arterioscl Throm Vas 26 (2006) 385-391
35. Landschulz K.T., Pathak R.K., Rigotti A.K.M., et al. Regulation of scavenger receptor, class B, type 1, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. Eur J Clin Invest 98 (1996) 984-995
36. Rigotti A., Trigatti B.L., Penman M., et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 94 (1997) 12610-12615
37. Fukushima H., Kugiyama K., Sugiyama S., et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 88 (2001) 1370-1373
38. Lamon-Fava S., Herrington D.M., Reboussin D.M., et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscl Throm Vas 28 (2008) 575-579
39. The Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
40. Miida T., Nakamura Y., Inano K., et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem 42 (1996) 1992-1995
41. Asztalos B.F., Batista M., Horvath K.V., et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscl Throm Vas 23 (2003) 847-852
42. Asztalos B.F., and Schaefer E.J. The effects of statins on high-density lipoproteins. Curr Atherosclerosis Rep 8 (2006) 41-49
43. Tilly-Kiesi M., Kahri J., Pyorala T., et al. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis 129 (1997) 249-259
44. Ansell B.J., Fonarow G.C., and Fogelman A.M. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18 (2007) 427-434
45. Lamon-Fava S., and Micherone D. Regulation of apo A-I gene expression: mechanism of action of estrogen and genistein. J Lipid Res 45 (2004) 106-112
46. Ouyang P., Tardif J.C., Herrington D.M., et al. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis 189 (2006) 375-386